PRIMARY STUDY
Design, synthesis, and biological evaluations of 5-aryl-pyrazole-3-carboxamide derivatives as selective CB2 receptor agonists for the treatment of colitis
Key Findings: This study identified a compound, #33, as one of the most potent leads, showing a remarkably high potency and selectivity at the CB2 receptor, and significantly attenuated colon inflammation.
Type of Study: Laboratory Study
Study Result: Positive
Research Location(s): China
Year of Pub: 2025
Cannabinoids Studied: Endocannabinoid (unspecified)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB2 agonist
Citation: Jiang BE, He Y, Chen J, Jiang XW, Qiu ZL, Liang QW, Gao XL, Zhang HK, Tian HG, Liu MY, Lu WQ, Yu LF. Design, synthesis, and biological evaluations of 5-aryl-pyrazole-3-carboxamide derivatives as selective CB2 receptor agonists for the treatment of colitis. Eur J Med Chem. 2025 Feb 5;283:117117. doi: 10.1016/j.ejmech.2024.117117. Epub 2024 Dec 2. PMID: 39653620.
